Sanofi (NASDAQ:SNY) Shares Bought by Ethic Inc.

Ethic Inc. lifted its holdings in Sanofi (NASDAQ:SNY) by 27.2% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 133,772 shares of the company’s stock after purchasing an additional 28,645 shares during the period. Ethic Inc.’s holdings in Sanofi were worth $7,269,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Sanofi by 124.0% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 24,131 shares of the company’s stock worth $1,344,000 after acquiring an additional 13,358 shares in the last quarter. Axxcess Wealth Management LLC increased its position in shares of Sanofi by 130.5% in the first quarter. Axxcess Wealth Management LLC now owns 10,234 shares of the company’s stock worth $568,000 after acquiring an additional 5,794 shares in the last quarter. Ballentine Partners LLC increased its position in shares of Sanofi by 68.7% in the first quarter. Ballentine Partners LLC now owns 26,063 shares of the company’s stock worth $1,445,000 after acquiring an additional 10,617 shares in the last quarter. Sowell Financial Services LLC purchased a new position in shares of Sanofi in the first quarter worth approximately $328,000. Finally, Farther Finance Advisors LLC increased its position in shares of Sanofi by 66.2% in the first quarter. Farther Finance Advisors LLC now owns 6,215 shares of the company’s stock worth $338,000 after acquiring an additional 2,476 shares in the last quarter. Institutional investors and hedge funds own 14.04% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on SNY. JPMorgan Chase & Co. upgraded shares of Sanofi from a “neutral” rating to an “overweight” rating in a report on Friday, August 8th. Barclays restated an “overweight” rating on shares of Sanofi in a report on Wednesday, July 2nd. Wall Street Zen upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a report on Saturday, August 2nd. Morgan Stanley set a $56.00 price target on shares of Sanofi in a report on Monday, June 2nd. Finally, Hsbc Global Res upgraded shares of Sanofi to a “strong-buy” rating in a report on Monday, April 28th. Two analysts have rated the stock with a hold rating, five have given a buy rating and three have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $62.00.

Sanofi Price Performance

NASDAQ SNY opened at $49.77 on Friday. The company has a quick ratio of 0.94, a current ratio of 1.27 and a debt-to-equity ratio of 0.19. The stock has a market capitalization of $122.21 billion, a PE ratio of 11.96, a price-to-earnings-growth ratio of 1.17 and a beta of 0.48. The company has a 50 day moving average price of $48.57 and a two-hundred day moving average price of $51.83. Sanofi has a 12-month low of $44.73 and a 12-month high of $60.12.

Sanofi (NASDAQ:SNY) last posted its earnings results on Thursday, July 31st. The company reported $0.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.96 by ($0.06). The business had revenue of $11.34 billion during the quarter, compared to analyst estimates of $9.91 billion. Sanofi had a net margin of 21.47% and a return on equity of 16.86%. Sanofi’s revenue was down 7.0% compared to the same quarter last year. During the same quarter last year, the firm earned $1.73 earnings per share. As a group, equities analysts predict that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.